This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 14 trials Clear all
Filter by:

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Iberdomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Iberdomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE, Nantes, France

Brief Summary

This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenancetreatment after transplant.

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

  • Status Recruiting
    Recruiting
  • Condition Lymphoma
    Lymphoma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-220, Drug: Rituximab, Drug: Obinutuzumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-220, Drug: Rituximab, Drug: Obinutuzumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic Phoenix, Phoenix, Arizona, United States

Brief Summary

This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification. Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Lupus Erythematosus, Systemic
    Lupus Erythematosus, Systemic
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: CC-220, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-220, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinical and Translational Research Center of Alabama, PC, Tuscaloosa, Alabama, United States

Brief Summary

The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus. Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: CC-220, Drug: Dexamethasone, Drug: Daratumumab - 16mg/kg, Drug: Bortezomib (BTZ), Drug: Carfilzomib, Drug: Daratumumab- 1800mg

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: CC-220, Drug: Dexamethasone, Drug: Daratumumab - 16mg/kg, Drug: Bortezomib (BTZ), Drug: Carfilzomib, Drug: Daratumumab- 1800mg

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic, Scottsdale, Arizona, United States

Brief Summary

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

NWZ, Alkmaar, Netherlands

Brief Summary

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

  • Status Recruiting
    Recruiting
  • Condition Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma,...
    Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma,...
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: JCAR017, Drug: Durvalumab, Drug: CC-122, Drug: Ibrutinib, Drug: CC-220, Drug: Relatlimab, Drug: Nivolumab, Drug: CC-99282

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: JCAR017, Drug: Durvalumab, Drug: CC-122, Drug: Ibrutinib, Drug: CC-220, Drug: Relatlimab, Drug: Nivolumab, Drug: CC-99282

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

City of Hope National Medical Center, Duarte, California, United States

Brief Summary

This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested: Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

  • Status Completed
    Completed
  • Condition Pharmacokinetics
    Pharmacokinetics
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-220, Drug: Rifampin, Drug: Itraconazole

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-220, Drug: Rifampin, Drug: Itraconazole

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

PPD Development, LP, Austin, Texas, United States

Brief Summary

This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel. A total of approximately 38 subjects will participate in this study, with approximately 19 subjects in Part 1 and approximately 19 subjects in Part 2. Each subject may only participate in one of the parts.

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

  • Status Completed
    Completed
  • Condition Hepatic Impairment, Healthy Volunteers
    Hepatic Impairment, Healthy Volunteers
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-220

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-220

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Brief Summary

This is a multicenter, open-label study to assess the PK of a single 1-mg oral dose of CC-220 in subjects with mild, moderate, and severe hepatic impairment, and in matched healthy control subjects with normal hepatic function. Degree of hepatic impairment will be determined during the Screening period by the subject's score according to Child-Pugh Classification Criteria

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

  • Status Completed
    Completed
  • Condition Healthy Volunteers
    Healthy Volunteers
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-220

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-220

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Quintiles Phase One Services, LLC, Overland Park, Kansas, United States

Brief Summary

This is an open-label, randomized, 2-period, 2-way crossover study to assess the relative bioavailability of a new CC-220 capsule formulation, compared to a reference CC-220 capsule formulation, after administration of single oral doses in healthy adult subjects under fasted conditions. Approximately 16 subjects will be assigned randomly to 1 of 2 treatment sequences. The sequences will dictate the order in which each subject receives the following treatments: - Treatment A (Reference): A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules. - Treatment B (Test): A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 Hydroxypropyl methylcellulose (HPMC) capsule.

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

  • Status Completed
    Completed
  • Condition Healthy
    Healthy
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: CC-220 0.03 mg, Drug: CC-220 0.1 mg, Drug: CC-220 0.3 mg, Drug: CC-220 1 mg, Drug: CC-220 2 mg, Drug: Placebo, Drug: CC-220, Drug: CC-220, Drug: CC-220

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: CC-220 0.03 mg, Drug: CC-220 0.1 mg, Drug: CC-220 0.3 mg, Drug: CC-220 1 mg, Drug: CC-220 2 mg, Drug: Placebo, Drug: CC-220, Drug: CC-220, Drug: CC-220

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Covance Clinical Research Unit, Madison, Wisconsin, United States

Brief Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of CC-220 and to explore the effect of food on the bioavailability of CC-220 in healthy subjects